About
BRAF-Inhibitors, In-licensing others
Areas of Focus
Categories
Small Molecule PharmaceuticalMiddle East
Team (2)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
500
By Phase
EARLY_PHASE1: 1PHASE1: 2PHASE2: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 5RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06610682Collaborator
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
EARLY_PHASE1Recruiting
15 participants
Started: Apr 7, 2025 · Completed: May 15, 2026
NCT06385119Lead Sponsor
A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.
PHASE1Completed
28 participants
Started: Apr 24, 2024 · Completed: Jan 7, 2025
NCT05503797Lead Sponsor
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
PHASE2Recruiting
254 participants
Started: Feb 21, 2023 · Completed: Dec 28, 2026
NCT02428712Lead Sponsor
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
PHASE1/PHASE2Completed
113 participants
Started: Apr 30, 2015 · Completed: Jul 12, 2024
NCT02274025Lead Sponsor
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
N/ACompleted
20 participants
Started: Oct 31, 2014 · Completed: Oct 31, 2016
Locations (1)
Headquarters
Rehovot, Israel
Map
Loading map...